The NIH Clinical Trial Integrity Act requires any sponsor seeking NIH approval of a clinical trial protocol for drugs, devices, biologics, or behavioral interventions to submit explicit, measurable goals and an operational plan for recruiting and retaining participants across race, ethnicity, age, and sex. Applications must include a rationale for targets, plans for separate subgroup analysis, training requirements, and consideration of less burdensome follow‑up options (telemedicine, wearable tech, alternate labs, etc.).
The bill builds enforcement through data flows and remediation rather than criminal penalties: sponsors must provide aggregate demographic and retention data to NIH during recruitment, post final disaggregated counts at trial end, and—if agreed targets are missed—submit and implement a strategic remediation plan within fixed timelines. The measure also mandates studies on reimbursement and safe‑harbor rules, authorizes a $10 million/year public awareness and grant program for 2027–2030, and applies Section 1557 nondiscrimination protections to covered trials.
At a Glance
What It Does
The bill makes NIH protocol approval contingent on application materials that set measurable recruitment and retention goals reflecting disease prevalence or the U.S. population, a written recruitment/retention strategy, training plans, and consideration of reduced‑burden follow‑up. It requires ongoing aggregate demographic reporting, annual retention reporting, final disaggregated enrollment counts, public posting of summaries, and remediation steps if targets are missed.
Who It Affects
Academic researchers and industry sponsors who seek NIH protocol approval; NIH program officers and grants management staff who will monitor compliance; community organizations and IRBs asked into recruitment and remediation planning; and patients from underrepresented demographic groups whose inclusion the bill seeks to increase.
Why It Matters
This bill shifts diversity from guidance to a binding condition on NIH approval and ties transparency (public posting) to recruitment outcomes. It creates new administrative and reporting obligations for sponsors, establishes remediation processes instead of fines, and pushes NIH to study cost‑barrier rules that can obstruct enrollment.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The Act makes explicit what NIH policy previously encouraged: every sponsor requesting NIH approval of a trial protocol must submit concrete diversity goals and an operational plan. The goals must map to race, ethnicity, age, and sex categories and either reflect the disease’s prevalence across those groups or mirror the U.S. population when prevalence is unknown.
The application must explain how the sponsor calculated subgroup sample sizes or, alternately, describe specific recruitment and retention strategies for each subgroup.
Beyond goal setting, the bill requires sponsors to describe operational safeguards: that subgroup analyses will be performed; how community partners or community IRBs will review plans; what lower‑burden follow‑up options (telehealth, home visits, wearable devices, alternate labs, flexible hours, use of primary care providers) the trial will permit; and what diversity and inequity training investigators and staff will receive. NIH may look to named advisory bodies (Equity Committee, Advisory Committee on Research on Women’s Health, National Advisory Council on Minority Health and Health Disparities, Tribal Health Research Coordinating Committee) when shaping or reviewing curricula.Compliance is monitored through repeated reports.
While recruitment and data collection are ongoing, sponsors must share aggregate demographic data with NIH and submit retention rates disaggregated by race, ethnicity, age, and sex at least annually (or more often if NIH requests). At trial close, sponsors must report final disaggregated participant counts.
Public transparency is built in: NIH will post an application‑level summary of disease prevalence versus trial representation and any remediation plans, redacting study design details to protect intellectual property and scientific integrity.If a trial misses agreed targets, the sponsor must develop, with community and advocacy input and in consultation with NIH, a strategic plan to boost participation and submit it within 90 days. The sponsor then must implement the plan within an additional NIH‑agreed 90‑day period; NIH can provide technical assistance.
The Act also carves out an administrative waiver for trials already NIH‑funded and ongoing as of enactment, and requires the Comptroller General to study federal actions addressing participation barriers and implementation challenges. Parallel to these requirements, NIH must complete a two‑year study assessing human‑subject regulation updates for reimbursing out‑of‑pocket costs and possible safe‑harbor modifications to avoid Anti‑Kickback or related conflicts.Finally, the bill funds a national public awareness campaign run by NIH and FDA, with a grants program (community organizations, faith groups, eligible colleges, national organizations, community pharmacies) to pilot outreach and cover administrative costs; it authorizes $10 million per year for fiscal years 2027–2030 for that effort.
Section 1557 nondiscrimination protections apply to covered trials, embedding civil‑rights guardrails in recruitment activity.
The Five Things You Need to Know
Sponsors must include clear, measurable recruitment and retention goals by race, ethnicity, age, and sex that reflect disease prevalence or the U.S. population when prevalence is unknown.
While recruitment is ongoing sponsors must provide NIH with aggregate demographic enrollment data and submit retention rates disaggregated by race, ethnicity, age, and sex at least annually or as requested.
If a trial fails to meet agreed diversity targets, the sponsor must develop a strategic remediation plan with community input and submit it to NIH within 90 days and implement it within a further NIH‑agreed 90 days; NIH may offer technical assistance.
NIH must publish on its website application‑level summaries comparing disease prevalence to trial representation (without disclosing study design) and post remediation plans publicly; ongoing NIH‑funded trials as of enactment are exempt and may receive waivers.
Section 3 directs NIH to complete a 2‑year study on updating human‑subject regulations for reimbursements/compensation and on safe‑harbor rules related to recruitment incentives; Section 4 authorizes $10 million per year for 2027–2030 for a national outreach and grant program.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Short title
Designates the bill as the "NIH Clinical Trial Integrity Act." This is purely a caption but signals congressional intent to treat trial diversity and integrity as a unified statutory objective moving forward.
Application requirements for NIH‑approved protocols
This subsection binds protocol approval to a multi‑part application packet: measurable recruitment/retention goals stratified by race, ethnicity, age, and sex; a rationale showing how subgroup sizes were calculated or what specific enrollment strategies will be used; a requirement to plan for separate subgroup analyses; named community review roles; and a menu of lower‑burden follow‑up options sponsors must consider. Practically, applicants must translate policy goals into sample‑size logic or pragmatic enrollment tactics before NIH will grant protocol approval.
Reporting, privacy, and public transparency
Subsection (b) makes compliance a condition of approval: aggregate demographic data must be shared with NIH during recruitment and retention rates submitted annually (or as requested) to the program officer and grants management specialist. Privacy is explicitly preserved—data must not include individually identifiable information and must comply with federal privacy law. Subsection (d) requires NIH to post public summaries of disease prevalence versus trial representation and the goals or justifications provided by applicants, with an explicit prohibition on disclosing study design details to protect proprietary methods and safety protocols.
Exceptions, remediation steps, and waivers
Subsection (c) allows an applicant to justify why recruiting particular demographic groups is not scientifically necessary; that is the only formal exception to the application requirements. If a trial misses agreed targets (subsection (e)), the sponsor must draft a strategic plan—developed with community and advocacy groups and in consultation with NIH—within 90 days and make that plan public (with study design redacted); the sponsor must then implement the plan within a further NIH‑agreed 90 days. Subsection (f) creates an administrative waiver for trials already NIH‑funded and ongoing at enactment and requires NIH to list granted waivers in the Public Health Service Act triennial report.
Oversight study and nondiscrimination
The Comptroller General (GAO) must study federal agency actions to reduce participation barriers and report to Congress within one year, giving lawmakers an evidence base on implementation gaps. Section 2(h) applies Section 1557 civil‑rights nondiscrimination protections to trials covered by this Act, which can implicate language access, disability accommodations, and other access requirements for recruitment and participation.
Study on cost barriers, reimbursement, and safe harbors
Requires NIH to complete a study within two years examining whether human‑subjects regulations (45 C.F.R. part 46) and related guidance should be modernized to authorize reimbursement of out‑of‑pocket expenses and compensation for time, and whether updates to administrative safe‑harbor rules (including Anti‑Kickback considerations) are needed. This is effectively an instruction to reconcile ethical protections with practical incentives that can increase participation but may raise regulatory or fraud‑and‑abuse concerns.
National awareness campaign and grants program
Directs NIH and FDA to run a national campaign to raise awareness and distribute materials to patients and clinicians, develop curricula for investigators and clinicians, and ensure meaningful access for limited English proficiency consumers. The section creates a grants program to test outreach strategies and cover administrative costs for community partners, with an explicit authorization of $10 million per year for fiscal years 2027–2030 for implementation.
Definitions
Defines 'clinical trial' consistent with prospective interventional human subject research and adopts the CFR definition of 'sponsor.' These definitions narrow the statute to interventional trials and align statutory language to regulatory terms sponsors already use when engaging with FDA and NIH.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Underrepresented patient groups (racial and ethnic minorities, older adults, women): The bill increases the likelihood that safety and efficacy evidence will be generated for these groups by requiring subgroup recruitment goals and separate analyses, which improves the applicability of trial results to their care.
- Community‑based organizations and local recruitment partners: The Act funds grants and mandates community consultation in remediation planning, creating new funding and formal roles for organizations that assist with outreach, education, and culturally tailored recruitment.
- Clinical investigators and health systems committed to inclusive trials: Investigators who already design inclusive protocols benefit from clearer expectations and public transparency that can increase participant trust and competitive advantage when seeking NIH approval.
Who Bears the Cost
- Industry sponsors and academic trial sponsors: Sponsors must develop detailed recruitment rationales, implement additional recruitment strategies, provide training, and support new reporting flows to NIH—costs that are real for smaller academic groups and early‑phase sponsors with limited budgets.
- NIH program officers and grants management specialists: The bill creates a monitoring load—receiving more frequent disaggregated reports, reviewing remediation plans, and potentially supplying technical assistance—without an explicit dedicated staffing appropriation.
- Institutional review boards and community IRBs: The statute elevates community review roles and training expectations, increasing review and engagement responsibilities that may strain volunteer or underfunded community boards.
Key Issues
The Core Tension
The central dilemma is between imposing enforceable recruitment and reporting requirements to correct decades of underrepresentation—and thereby improve the evidence base for diverse patients—and the practical burdens those requirements impose on trial timelines, costs, and statistical design; stricter diversity conditions can improve external validity but also slow or deter trials unless paired with funding, regulatory clarity on incentives, and realistic statistical approaches.
The bill converts aspirational inclusion guidance into condition‑of‑approval obligations, but it leaves several operational and enforcement questions open. It ties goals to disease prevalence or the U.S. population, yet prevalence data are often incomplete or geographically variable; the statute does not prescribe a single epidemiologic source or method for calculating subgroup sample sizes, leaving room for inconsistency and disputes between sponsors and NIH about what constitutes a 'reasonable' target.
The remediation regime focuses on plans and implementation timelines rather than explicit financial or procedural penalties, which may limit NIH’s leverage if sponsors repeatedly underperform.
Statistical and scientific trade‑offs are under‑addressed. Requiring enrollment 'in sufficient numbers' for clinically and statistically meaningful subgroup determinations will raise sample‑size requirements, extend recruitment periods, and increase costs—especially for rare diseases—potentially shifting trial design toward larger, costlier studies or discouraging private investment in certain trials.
The bill also triggers privacy and data‑use issues: NIH will publicly post summaries that compare prevalence to representation, but sponsors will need clear guidance on aggregation thresholds and de‑identification to avoid re‑identification risks and to comply with HIPAA and other protections. Additionally, the directive to study reimbursement and safe‑harbor rules recognizes that paying or compensating participants can help recruitment but sits uneasily against anti‑fraud statutes; the outcome of those studies will materially affect what recruitment incentives are lawful.
Finally, the waiver for ongoing NIH‑funded trials and the absence of explicit sanctions create potential unevenness: new trials will face stricter administrative burdens while existing trials can continue under prior rules. That raises fairness and competitive concerns and may produce a temporary bifurcated evidence base unless NIH manages waivers and reporting transparency carefully.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.